CandlesenseCandlesense
AZN•benzinga•

AstraZeneca Doses First Patient In DESTINY-Endometrial01 Phase 3 Trial Evlauating ENHERTU In Combination With Rilvegostomig Or Pembrolizumab Versus Platinum-Based Chemotherapy In Combination With Pembrolizumab As First-Line Therapy In Patients With HER2 E

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 9, 2025 by benzinga

← Back to AZN News
    AstraZeneca Doses First Patient In DESTINY-Endometrial01 Phase 3 Trial Evlauating ENHERTU In Combination With Rilvegostomig Or Pembrolizumab Versus Platinum-Based Chemotherapy In Combination With Pembrolizumab As First-Line Therapy In Patients With HER2 E | AZN Stock News | Candlesense